India's High Technology Deficit : Science and Engineering Indicators
India's High Technology Deficit : Science and Engineering Indicators
India's High Technology Deficit : Science and Engineering Indicators
Chinas success as a hitech producer has indeed been dependent on its success on the
export front, which is reflected in the evidence that its presence in global hi-tech trade
was substantial. Its share in global hi-tech manufacturing exports rose from a little
more than 7.6 per cent in 1997 to well above 17 per cent after 2009 (Chart 3). This
rise paralleled a decline in the shares of both the US and the EU in global trade in
these products. On the other hand, India has been and remains a non-existent player in
global markets for high technology manufacturing, with a small increase in export
share from 0.5 to 1.9 per cent.
What is of special interest is the structure of the hi-tech manufacturing sectors in these
countries. In the case of China, in the period before the global crisis, semi-conductors,
communications and more recently computers and office machinery dominated. It
was only when the crisis affected exports in these areas that pharmaceuticals acquired
a larger share (Chart 3). In sum, information technology hardware is central to
Chinas hi-tech success. On the other hand, though India is considered an information
technology power, the three information technology-related sectors (semiconductors,
communications and computers), which accounted for around 35 per cent of hi-tech
value added in 1997, contributed just about 22 per cent of that value added in 2012.
In fact, the industries that have come to dominate the hi-tech sector in China are the
same as those in the developed countries, reflecting its ability to displace local
producers in those markets. The structure of Indias hi-tech sector on other hand was
completely different. What is noteworthy is the high share of pharmaceuticals in
Indias hi-tech industries. That sector accounted for 57 per cent of value added in
1997 and a dominant 68 per cent in 2012. It is well known that Indias pharmaceutical
prowess came as a result of a combination of protection for domestic production,
control over the operations of foreign firms in India, and, above all, a patenting
regime that recognized process patents and not product patents. These were all
policies typical of the interventionist, import substituting strategy of development
adopted during the first three decades after Independence. The result was the growth
of a large and diverse pharmaceutical industry that could ensure the availability of
good quality drugs at prices that were among the lowest in the world. The capacities
and technological capabilities built up during that time has meant that even though
India has given up many of these policies and today recognises product patents as
well, it is in a position to compete globally in many drugs that are off patent or are on
the way to being so.
in 2007, and then spiked to reach $25.6 billion in 2012. This makes pharmaceutical
production and exports the most successful components of Indias otherwise dismal
hi-tech manufacturing performance. It is not Indias two-and-a-half decades of
liberalisation and reform, but the strength created during the import substitution
years that drives hitech manufacturing in India. By allowing international firms with
deep pockets to enter and take over Indias pharma producers the government may be
giving up even that advantage.
* This article was originally published in the Business Line on August 4, 2014.